The Development and Use of Reporter Influenza B Viruses
- PMID: 31404985
- PMCID: PMC6723853
- DOI: 10.3390/v11080736
The Development and Use of Reporter Influenza B Viruses
Abstract
Influenza B viruses (IBVs) are major contributors to total human influenza disease, responsible for ~1/3 of all infections. These viruses, however, are relatively less studied than the related influenza A viruses (IAVs). While it has historically been assumed that the viral biology and mechanisms of pathogenesis for all influenza viruses were highly similar, studies have shown that IBVs possess unique characteristics. Relative to IAV, IBV encodes distinct viral proteins, displays a different mutational rate, has unique patterns of tropism, and elicits different immune responses. More work is therefore required to define the mechanisms of IBV pathogenesis. One valuable approach to characterize mechanisms of microbial disease is the use of genetically modified pathogens that harbor exogenous reporter genes. Over the last few years, IBV reporter viruses have been developed and used to provide new insights into the host response to infection, viral spread, and the testing of antiviral therapeutics. In this review, we will highlight the history and study of IBVs with particular emphasis on the use of genetically modified viruses and discuss some remaining gaps in knowledge that can be addressed using reporter expressing IBVs.
Keywords: Influenza B virus; molecular virology; reporter virus; reverse genetics; viral genetic engineering.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Hemagglutinin Cleavability, Acid Stability, and Temperature Dependence Optimize Influenza B Virus for Replication in Human Airways.J Virol. 2019 Dec 12;94(1):e01430-19. doi: 10.1128/JVI.01430-19. Print 2019 Dec 12. J Virol. 2019. PMID: 31597759 Free PMC article.
-
A Single Amino Acid in the Polymerase Acidic Protein Determines the Pathogenicity of Influenza B Viruses.J Virol. 2018 Jun 13;92(13):e00259-18. doi: 10.1128/JVI.00259-18. Print 2018 Jul 1. J Virol. 2018. PMID: 29643248 Free PMC article.
-
Replication-competent fluorescent-expressing influenza B virus.Virus Res. 2016 Feb 2;213:69-81. doi: 10.1016/j.virusres.2015.11.014. Epub 2015 Nov 15. Virus Res. 2016. PMID: 26590325 Free PMC article.
-
Existing Evidence for Influenza B Virus Adaptations to Drive Replication in Humans as the Primary Host.Viruses. 2023 Sep 30;15(10):2032. doi: 10.3390/v15102032. Viruses. 2023. PMID: 37896807 Free PMC article. Review.
-
Replication-Competent Influenza A Viruses Expressing Reporter Genes.Viruses. 2016 Jun 23;8(7):179. doi: 10.3390/v8070179. Viruses. 2016. PMID: 27347991 Free PMC article. Review.
Cited by
-
A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.J Virol. 2022 Aug 10;96(15):e0068922. doi: 10.1128/jvi.00689-22. Epub 2022 Jul 12. J Virol. 2022. PMID: 35862698 Free PMC article.
-
Host Protective Immune Responses against Influenza A Virus Infection.Viruses. 2020 May 3;12(5):504. doi: 10.3390/v12050504. Viruses. 2020. PMID: 32375274 Free PMC article. Review.
-
Next-generation vaccines for influenza B virus: advancements and challenges.Arch Virol. 2025 Jan 6;170(2):25. doi: 10.1007/s00705-024-06210-4. Arch Virol. 2025. PMID: 39762648 Review.
-
Cellular glycan modification by B3GAT1 broadly restricts influenza virus infection.Nat Commun. 2022 Oct 29;13(1):6456. doi: 10.1038/s41467-022-34111-0. Nat Commun. 2022. PMID: 36309510 Free PMC article.
-
A potential Chinese medicine monomer against influenza A virus and influenza B virus: isoquercitrin.Chin Med. 2023 Nov 2;18(1):144. doi: 10.1186/s13020-023-00843-4. Chin Med. 2023. PMID: 37919750 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical